Takayoshi Tanaka - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Takayoshi Tanaka

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Nature Communications|September 7, 2022

Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumoursYuji Sano, Yumiko Azuma, Toshiaki Tsunenari, et al.

Journal of Hepatology|April 18, 2016

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.

Cancer Chemotherapy and Pharmacology|January 26, 2017

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Nature Communications|September 7, 2022

Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumoursYuji Sano, Yumiko Azuma, Toshiaki Tsunenari, et al.

Journal of Hepatology|April 18, 2016

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.

Cancer Chemotherapy and Pharmacology|January 26, 2017

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.

Pageof 2